Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Cue Biopharma
Baylor College of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Universitätsklinikum Hamburg-Eppendorf
Bayer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
National Cancer Institute (NCI)
Sumitomo Pharma America, Inc.
New York Medical College
Children's National Research Institute
City of Hope Medical Center
Emory University
Emory University
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of South Florida
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vanderbilt University
National Cancer Institute (NCI)